These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21400884)

  • 1. [Prevention of hypertension by drugs and immunization against angiotensin II].
    Mitsuyama S
    Nihon Naika Gakkai Zasshi; 2011 Feb; 100(2):446-52. PubMed ID: 21400884
    [No Abstract]   [Full Text] [Related]  

  • 2. A vaccine for hypertension.
    Ménard J
    J Hypertens; 2007 Jan; 25(1):41-6. PubMed ID: 17143170
    [No Abstract]   [Full Text] [Related]  

  • 3. Renin-angiotensin-aldosterone system blockade is safe and effective in elderly hypertensive patients with and without impaired renal function.
    Ferri C; Ferri L
    High Blood Press Cardiovasc Prev; 2012 Dec; 19(4):197-8. PubMed ID: 23430662
    [No Abstract]   [Full Text] [Related]  

  • 4. Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?
    Neldam S
    Future Cardiol; 2010 Jan; 6(1):129-35. PubMed ID: 20014992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
    Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
    Trials; 2015 Dec; 16():581. PubMed ID: 26686682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
    Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
    MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381
    [No Abstract]   [Full Text] [Related]  

  • 8. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Serebruany VL; Atar D; Hanley DF
    Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
    [No Abstract]   [Full Text] [Related]  

  • 9. [CHARM].
    Momomura S
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():431-6. PubMed ID: 16981575
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug dosing for renoprotection: maybe it's time for a drug efficacy-safety score?
    de Zeeuw D; Lambers-Heerspink H
    J Am Soc Nephrol; 2009 Apr; 20(4):688-9. PubMed ID: 19279124
    [No Abstract]   [Full Text] [Related]  

  • 11. [Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection].
    MMW Fortschr Med; 2007 Dec; 149(49-50):52-3. PubMed ID: 18236984
    [No Abstract]   [Full Text] [Related]  

  • 12. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
    Oparil S; Kjeldsen SE; Hedner T; Narkiewicz K
    Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085
    [No Abstract]   [Full Text] [Related]  

  • 13. ARBs for cardiovascular and renal protection in high-risk patients.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(4):224. PubMed ID: 21881697
    [No Abstract]   [Full Text] [Related]  

  • 14. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
    Middeke M
    Dtsch Med Wochenschr; 2012 Nov; 137(48):2498. PubMed ID: 23168983
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.
    Grandi AM; Solbiati F; Laurita E; Maresca AM; Nicolini E; Marchesi C; Gianni M; Guasti L; Venco A
    Am J Hypertens; 2008 Feb; 21(2):231-7. PubMed ID: 18174880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New studies on hypertension of great significance to clinical practice. Also very old persons benefit from blood pressure reduction].
    Nilsson PM
    Lakartidningen; 2008 May 7-13; 105(19):1382-4. PubMed ID: 18574975
    [No Abstract]   [Full Text] [Related]  

  • 17. [spACE, the last frontier? Renin inhibition in hypertension].
    Villa L
    G Ital Nefrol; 2008; 25(3):274. PubMed ID: 18473295
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
    Sharma A; Baliga V;
    J Indian Med Assoc; 2008 Mar; 106(3):191-4, 196. PubMed ID: 18712142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan].
    Ishii M
    Nihon Rinsho; 2004 Jan; 62(1):193-202. PubMed ID: 14737853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACE inhibitors in cardiovascular disease--unbeatable?
    McMurray JJ
    N Engl J Med; 2008 Apr; 358(15):1615-6. PubMed ID: 18378521
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.